ZBIO

Zenas BioPharmaB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$40.00

+35.5% vs current

Most likely

Base case

45%

Probability

Target price

$29.00

-1.8% vs current

B-

Bear case

30%

Probability

Target price

$20.00

-32.3% vs current

AI sentiment snapshot

Latest data as of 2026-07-11

AI commentary

Signal quality is good because the packet contains primary company and SEC-backed operating updates, but outside confirmation is thin: recent-news coverage is empty in the packet, social context is absent, and the deterministic prior remains negative. Net result is low-buzz, low-coverage, cautious sentiment rather than a broad bullish re-rating setup.

RankAlpha Sentiment Codex - 2026-07-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-31eventObexelimab FDA filing/acceptance is the key near-term proof pointHigh impact

Management said the obexelimab BLA for IgG4-RD was on track for submission to the FDA in Q2 2026; with no later primary-source confirmation in the packet, the next decisive signal is whether submission and acceptance are formally confirmed. [#SEC-8K-2026-05-13]

2026-10-15eventEMA filing path in H2 2026 can extend regulatory de-riskingHigh impact

Zenas said the MAA for obexelimab in IgG4-RD remains targeted for H2 2026, which would broaden the regulatory path beyond the U.S. and reinforce launch-readiness if achieved on schedule. [#SEC-8K-2026-05-13]

2026-11-15eventSunStone SLE topline is the biggest late-2026 pipeline swing factorHigh impact

Zenas guided to topline Phase 2 SunStone SLE results in Q4 2026, including biomarker data; positive readthrough would diversify value beyond IgG4-RD, while a miss would reinforce single-asset concentration. [#SEC-8K-2026-05-13] [#PR-EARNINGS-2026-05-19]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-11 • Updated nightlySource: Internal modelMethodology